Piper Sandler analyst David Westenberg lowered the firm’s price target on Quest Diagnostics (DGX) to $190 from $200 following quarterly results. The firm keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics: Strong Volume Growth and Strategic Partnerships Drive Buy Rating
- Quest Diagnostics price target raised to $185 from $180 at Evercore ISI
- Quest Diagnostics price target raised to $191 from $182 at Morgan Stanley
- Quest Diagnostics price target raised to $180 from $175 at UBS
- Quest Diagnostics price target raised to $192 from $190 at Truist